Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up

Detalhes bibliográficos
Autor(a) principal: Pellegrini,Denise Oliveira
Data de Publicação: 2014
Outros Autores: Gomes,Vitor Osório, Lasevitch,Ricardo, Smidt,Luis, Azeredo,Marco Aurélio, Ledur,Priscila, Bodanese,Rodrigo, Sinnott,Leonardo, Moriguchi,Emílio, Caramori,Paulo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos Brasileiros de Cardiologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2014002100002
Resumo: Background: Drug-eluting stents have been used in daily practice since 2002, with the clear advantages of reducing the risk of target vessel revascularization and an impressive reduction in restenosis rate by 50%-70%. However, the occurrence of a late thrombosis can compromise long-term results, particularly if the risks of this event were sustained. In this context, a registry of clinical cases gains special value. Objective: To evaluate the efficacy and safety of drug-eluting stents in the real world. Methods: We report on the clinical findings and 8-year follow-up parameters of all patients that underwent percutaneous coronary intervention with a drug-eluting stent from January 2002 to April 2007. Drug-eluting stents were used in accordance with the clinical and interventional cardiologist decision and availability of the stent. Results: A total of 611 patients were included, and clinical follow-up of up to 8 years was obtained for 96.2% of the patients. Total mortality was 8.7% and nonfatal infarctions occurred in 4.3% of the cases. Target vessel revascularization occurred in 12.4% of the cases, and target lesion revascularization occurred in 8% of the cases. The rate of stent thrombosis was 2.1%. There were no new episodes of stent thrombosis after the fifth year of follow-up. Comparative subanalysis showed no outcome differences between the different types of stents used, including Cypher®, Taxus®, and Endeavor®. Conclusion: These findings indicate that drug-eluting stents remain safe and effective at very long-term follow-up. Patients in the "real world" may benefit from drug-eluting stenting with excellent, long-term results.
id SBC-1_fb81a6a388e5fe8772e08e9a2459acd3
oai_identifier_str oai:scielo:S0066-782X2014002100002
network_acronym_str SBC-1
network_name_str Arquivos Brasileiros de Cardiologia (Online)
repository_id_str
spelling Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-UpDrug-Eluting Stents/trendsTreatment OutcomeEffectivenessLong-Term Effect Background: Drug-eluting stents have been used in daily practice since 2002, with the clear advantages of reducing the risk of target vessel revascularization and an impressive reduction in restenosis rate by 50%-70%. However, the occurrence of a late thrombosis can compromise long-term results, particularly if the risks of this event were sustained. In this context, a registry of clinical cases gains special value. Objective: To evaluate the efficacy and safety of drug-eluting stents in the real world. Methods: We report on the clinical findings and 8-year follow-up parameters of all patients that underwent percutaneous coronary intervention with a drug-eluting stent from January 2002 to April 2007. Drug-eluting stents were used in accordance with the clinical and interventional cardiologist decision and availability of the stent. Results: A total of 611 patients were included, and clinical follow-up of up to 8 years was obtained for 96.2% of the patients. Total mortality was 8.7% and nonfatal infarctions occurred in 4.3% of the cases. Target vessel revascularization occurred in 12.4% of the cases, and target lesion revascularization occurred in 8% of the cases. The rate of stent thrombosis was 2.1%. There were no new episodes of stent thrombosis after the fifth year of follow-up. Comparative subanalysis showed no outcome differences between the different types of stents used, including Cypher®, Taxus®, and Endeavor®. Conclusion: These findings indicate that drug-eluting stents remain safe and effective at very long-term follow-up. Patients in the "real world" may benefit from drug-eluting stenting with excellent, long-term results. Sociedade Brasileira de Cardiologia - SBC2014-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2014002100002Arquivos Brasileiros de Cardiologia v.103 n.3 2014reponame:Arquivos Brasileiros de Cardiologia (Online)instname:Sociedade Brasileira de Cardiologia (SBC)instacron:SBC10.5935/abc.20140110info:eu-repo/semantics/openAccessPellegrini,Denise OliveiraGomes,Vitor OsórioLasevitch,RicardoSmidt,LuisAzeredo,Marco AurélioLedur,PriscilaBodanese,RodrigoSinnott,LeonardoMoriguchi,EmílioCaramori,Pauloeng2014-10-21T00:00:00Zoai:scielo:S0066-782X2014002100002Revistahttp://www.arquivosonline.com.br/https://old.scielo.br/oai/scielo-oai.php||arquivos@cardiol.br1678-41700066-782Xopendoar:2014-10-21T00:00Arquivos Brasileiros de Cardiologia (Online) - Sociedade Brasileira de Cardiologia (SBC)false
dc.title.none.fl_str_mv Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up
title Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up
spellingShingle Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up
Pellegrini,Denise Oliveira
Drug-Eluting Stents/trends
Treatment Outcome
Effectiveness
Long-Term Effect
title_short Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up
title_full Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up
title_fullStr Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up
title_full_unstemmed Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up
title_sort Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up
author Pellegrini,Denise Oliveira
author_facet Pellegrini,Denise Oliveira
Gomes,Vitor Osório
Lasevitch,Ricardo
Smidt,Luis
Azeredo,Marco Aurélio
Ledur,Priscila
Bodanese,Rodrigo
Sinnott,Leonardo
Moriguchi,Emílio
Caramori,Paulo
author_role author
author2 Gomes,Vitor Osório
Lasevitch,Ricardo
Smidt,Luis
Azeredo,Marco Aurélio
Ledur,Priscila
Bodanese,Rodrigo
Sinnott,Leonardo
Moriguchi,Emílio
Caramori,Paulo
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pellegrini,Denise Oliveira
Gomes,Vitor Osório
Lasevitch,Ricardo
Smidt,Luis
Azeredo,Marco Aurélio
Ledur,Priscila
Bodanese,Rodrigo
Sinnott,Leonardo
Moriguchi,Emílio
Caramori,Paulo
dc.subject.por.fl_str_mv Drug-Eluting Stents/trends
Treatment Outcome
Effectiveness
Long-Term Effect
topic Drug-Eluting Stents/trends
Treatment Outcome
Effectiveness
Long-Term Effect
description Background: Drug-eluting stents have been used in daily practice since 2002, with the clear advantages of reducing the risk of target vessel revascularization and an impressive reduction in restenosis rate by 50%-70%. However, the occurrence of a late thrombosis can compromise long-term results, particularly if the risks of this event were sustained. In this context, a registry of clinical cases gains special value. Objective: To evaluate the efficacy and safety of drug-eluting stents in the real world. Methods: We report on the clinical findings and 8-year follow-up parameters of all patients that underwent percutaneous coronary intervention with a drug-eluting stent from January 2002 to April 2007. Drug-eluting stents were used in accordance with the clinical and interventional cardiologist decision and availability of the stent. Results: A total of 611 patients were included, and clinical follow-up of up to 8 years was obtained for 96.2% of the patients. Total mortality was 8.7% and nonfatal infarctions occurred in 4.3% of the cases. Target vessel revascularization occurred in 12.4% of the cases, and target lesion revascularization occurred in 8% of the cases. The rate of stent thrombosis was 2.1%. There were no new episodes of stent thrombosis after the fifth year of follow-up. Comparative subanalysis showed no outcome differences between the different types of stents used, including Cypher®, Taxus®, and Endeavor®. Conclusion: These findings indicate that drug-eluting stents remain safe and effective at very long-term follow-up. Patients in the "real world" may benefit from drug-eluting stenting with excellent, long-term results.
publishDate 2014
dc.date.none.fl_str_mv 2014-09-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2014002100002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2014002100002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/abc.20140110
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Cardiologia - SBC
publisher.none.fl_str_mv Sociedade Brasileira de Cardiologia - SBC
dc.source.none.fl_str_mv Arquivos Brasileiros de Cardiologia v.103 n.3 2014
reponame:Arquivos Brasileiros de Cardiologia (Online)
instname:Sociedade Brasileira de Cardiologia (SBC)
instacron:SBC
instname_str Sociedade Brasileira de Cardiologia (SBC)
instacron_str SBC
institution SBC
reponame_str Arquivos Brasileiros de Cardiologia (Online)
collection Arquivos Brasileiros de Cardiologia (Online)
repository.name.fl_str_mv Arquivos Brasileiros de Cardiologia (Online) - Sociedade Brasileira de Cardiologia (SBC)
repository.mail.fl_str_mv ||arquivos@cardiol.br
_version_ 1752126564707860480